 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Over the last three days, A.I.dvisor has detected that DMAC's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

DiaMedica Therapeutics (DMAC, $3.24) Aroon Indicator entered an Uptrend on September 15, 2023.

DiaMedica Therapeutics (DMAC, $3.24) Aroon Indicator entered an Uptrend on September 13, 2023.

DiaMedica Therapeutics (DMAC, $3.28) Aroon Indicator entered an Uptrend on September 12, 2023.

This price move could indicate a change in the trend, and may be a sell signal for investors...

DiaMedica Therapeutics (DMAC, $3.28) price exceeded its 50-day Moving Average on September 12, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the...

DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer

This price move could indicate a change in the trend, and may be a buy signal for investors...

DiaMedica Therapeutics (DMAC, $3.43) price moved above its 50-day Moving Average on September 11, 2023

DiaMedica Therapeutics (DMAC, $3.38) price moved above its 50-day Moving Average on September 06, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced that Rick Pauls, its...

DiaMedica Therapeutics to Participate at Lake Streets 7th Annual Best Ideas Growth Conference

DiaMedica Therapeutics Inc. (DMAC) Q2 2023 Earnings Call Transcript

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a...

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

Watchers	1,432
52-Wk Low	$1.12
52-Wk High	$4.75

Market Cap	$99.05M
Volume (M)	3,710.00
52-Wk High	$4.75
52-Wk Low	$1.12

DMAC DiaMedica Therapeutics Inc

About

Feed

News

Earnings

Fundamentals